# Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

> **NCT05618366** · PHASE1 · TERMINATED · sponsor: **Weill Medical College of Cornell University** · enrollment: 3 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Tazemetostat

## Key facts

- **NCT ID:** NCT05618366
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-06-07
- **Primary completion:** 2026-02-27
- **Final completion:** 2026-02-27
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05618366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05618366, "Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05618366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*